CGEN.TA(CGEN.TA)
CGEN.TA
Compugen Ltd. is a biotechnology company focused on discovering and developing novel immuno-oncology therapies. Its proprietary computational discovery platform enables the identification of unique drug candidates, particularly in the treatment of cancer, positioning it competitively in the oncology space.
Compugen generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, leveraging its proprietary technology to develop immuno-oncology therapies. The high gross margin of 87.3% reflects the low cost of goods sold associated with its research-driven model, while its operating margin of 43.1% indicates strong profitability from its collaborations.
Progress in clinical trials for lead drug candidates, particularly CGEN-15001T
New partnership announcements with major pharmaceutical companies
Regulatory approvals for drug candidates
Market sentiment towards immuno-oncology therapies
Regulatory changes impacting drug approval processes
Technological disruption in drug discovery methodologies
Emergence of new competitors in the immuno-oncology space
Potential for larger pharmaceutical companies to develop similar therapies in-house
Low cash reserves could limit operational flexibility if partnerships do not materialize
Dependence on external funding for R&D initiatives
low - The biotechnology sector is generally less sensitive to economic cycles as healthcare spending tends to be more stable.
Moderate - Rising interest rates could increase the cost of capital for future funding rounds, but the company is currently low on debt, mitigating this risk.
minimal - Compugen has a low debt-to-equity ratio of 0.03, indicating minimal reliance on credit.
growth - Investors are likely attracted to the high revenue growth potential and innovative drug pipeline.
high - The stock has exhibited significant volatility, reflecting the high-risk nature of biotech investments.